- Substantially lower rates of febrile neutropenia and sepsis in patients receiving Iomab-B compared to patients receiving salvage chemotherapy in the control arm
- 78 percent of patients in the Iomab-B arm are potentially evaluable for the primary endpoint compared to 13 percent in the control arm after factoring in 100-day non-relapse transplant related mortality
- Key protocol amendment allowing patients failing venetoclax induction therapy to enroll in the SIERRA trial is expected to increase eligible patient pool
PR Newswire
NEW YORK, Feb. 21, 2020
